The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique

British Journal of Clinical Pharmacology

Volumn 55, Issue 2, 2003, Pages 182-190

  Tannergren, Christer ^a   Knutson, Tina ^b   Knutson, Lars ^b   Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bioavailability; Biopharmaceutics Classification System; Drug absorption; Drug drug interaction; Fexofenadine; Intestinal permeability; Ketoconazole; P glycoprotein

Indexed keywords

FEXOFENADINE; KETOCONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG CONCENTRATION; DRUG EFFECT; DRUG PENETRATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTESTINE MUCOSA PERMEABILITY; JEJUNUM; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; OPEN STUDY; PERFUSION; PRIORITY JOURNAL; PROTEIN TRANSPORT; TIME SERIES ANALYSIS;

ADULT; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; INTESTINAL ABSORPTION; JEJUNUM; KETOCONAZOLE; MALE; PERMEABILITY; TERFENADINE;

EID: 0344687432     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01722.x     Document Type: Article

References (38)

1. Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000; 59: 301-321.
2. Robbins DK, Castles MA, Pack DJ, Bhargava VO, Weir S. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998; 19: 455-463.
3. Lippert C, Ling J, Brown P et al. Mass balance and pharmacokinetics of MDL 16,455A in healthy male volunteers. Pharm Res 1996; 12: S390.
4. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequenses. JAMA 1993; 269: 1513-1518.
5. Davit B, Reynolds K, Yuan R et al. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol 1999; 39: 899-910.
6. Kosoglou T, Salfi M, Lim JM, Batra VK, Cayen MN, Affrime MB. Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine. Br J Clin Pharmacol 2000; 50: 581-589.
7. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001; 69: 114-121.
8. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-398.
9. Nakamura T, Sakeda T, Ohmoto N et al. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab Dispos 2002; 30: 4-6.
10. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999; 27: 866-871.
11. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res 1999; 16: 478-485.
12. Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. Br J Clin Pharmacol 2001; 52: 107-117.
13. Lennernäs H, Ahrenstedt Ö, Hällgren R, Knutsson L, Ryde M, Paalzow L. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm Res 1992; 9: 1243-1251.
14. Lennernäs H. Human intestinal permeability. J Pharm Sci 1998; 87: 403-410.
15. Lennernäs H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol 1997; 49: 627-638.
16. Lindahl A, Sandström R, Ungell A-L et al. Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin Pharmacol Ther 1996; 60: 493-503.
17. Sandström R, Knutson TW, Knutson L, Jansson B, Lennernäs H. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br J Clin Pharmacol 1999; 48: 180-189.
18. Amidon GL, Lennernäs HL, Shah VP, Crison J. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
19. Food and Drug Administration. Guidance for Industry: Waiver of in Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System 2000: http://www.fda.gov/cder/guidance/3618fnl.htm
20. Knutson L, Odlind B, Hallgren R. A new technique for segmental jejunal perfusion in man. Am J Gastroenterol 1989; 84: 1278-1284.
21. Lennernäs H, Lee I-D, Fagerholm U, Amidon GL. A residence-time distribution analysis of the hydrodynamics within the intestine in man during a regional single-pass perfusion with Loc-I-Gut: in vivo permeability estimation. J Pharm Pharmacol 1997; 49: 682-686.
22. Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 1996; 60: 601-607.
23. Siegsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman MM. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 1994; 151: 485-491.
24. Kim RB, Wandel C, Leake B et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16: 408-414.
25. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 1998; 358: 289-294.
26. Zhang Y, Hsieh Y, Izumi T, Lin ET, Benet LZ. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J Pharmacol Exp Ther 1998; 287: 246-252.
27. Woodland C, Ito S, Koren G. A model for the prediction of digoxin drug interactions at the renal tubular cell level. Ther Drug Monit 1998; 20: 134-138.
28. Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-199.
29. Drescher S, Schaeffeler E, Hitzl M et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002; 53: 526-534.
30. Tamai I, Nezu J-I, Uchino H et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000; 273: 251-260.
31. Dresser GK, Bailey DG, Leake BF. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002; 71: 11-20.
32. Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 (CYP3A) in human intestinal and liver microsomes. Comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 1999; 27: 180-187.
33. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 1994; 34: 1222-1227.
34. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 2000; 58: 624-632.
35. Hilgendorf C, Spahn-Langguth H, Regardh CG, Lipka E, Amidon GL, Langguth P. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci 2000; 89: 63-75.
36. Van den Bossche H, Willemsens G, Cools W, Cornelissen F, Lauwers WF, Van Cutsem JM. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother 1980; 17: 922-928.
37. Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernäs H, Karlén A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem 1998; 41: 4939-4949.
38. Palm K, Stenberg P, Luthman K, Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 1997; 14: 568-571.